Skip to content
lifestyle.recentlegalnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Antengene Corporation Limited
Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
September 20, 2026
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
September 14, 2026
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
August 24, 2026
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
August 23, 2026
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
August 18, 2026